Target RM2.64
The 9MFY09 results were above expectations, contributed by a higher nitrile gloves sales mix, stronger US$, higher production capacity and more efficient cost control. This led to an EBITDA margin improvement of 1.6%-pts to 22.9% YTD while core net profit was up 20.8% q-o-q and 96.2% YTD. We like Hartalega for its market leadership in the production of high quality nitrile examination gloves.
FY09-10 earnings upgrade. We are upgrading our FY09-10 earnings forecasts by 17- 38% to take into account of the better performance of Hartalega. Maintain Buy. Our target price is revised upwards to RM2.64 (previously RM2.25) based on a PER of 8x FY10 earnings. Besides having a market leadership in nitrile gloves in Malaysia, we understand that Hartalega also has the most advanced glove manufacturing technology among its peers. Having said that, the risks to our view include: 1) fluctuating nitrile latex prices, since nitrile latex makes up about 50% of its total production cost; 2) uncertainty in crude oil price direction, causing uncertainty in raw material prices, 3) weakening of US$, since the bulk of its sales are exported, and 4) high reliance on 2 major customers, Medline and Microflex, which make up more than 50% of total sales.
more....
from http://bursastreet.blogspot.com/2009/02/ha...a-holdings.html
Hartalega Holdings, Harta-Make ur harta by buying
Feb 17 2009, 09:53 PM, updated 17y ago
Quote
0.0172sec
1.31
5 queries
GZIP Disabled